Christie Dose for High-Dose Palliative Head and Neck/Oral Cavity Cancer
The Christie high-dose palliative radiotherapy regimen delivers 50 Gy in 16 fractions over 3.2 weeks (3.125 Gy per fraction), typically using parallel opposed fields. 1, 2
Regimen Specifications
The Christie scheme is a hypofractionated palliative approach specifically designed for advanced head and neck squamous cell carcinoma patients who are not candidates for curative treatment:
- Total dose: 50 Gy
- Fractionation: 16 fractions of 3.125 Gy each
- Treatment duration: 3.2 weeks (approximately 22 days)
- Technique: Parallel pair field technique, historically delivered via Cobalt-60 machines 1
Clinical Outcomes and Evidence
This regimen demonstrates clinically meaningful palliative benefit in resource-constrained or non-curative settings. In a prospective study of 158 patients, the Christie scheme achieved an overall response rate of 73% (45% complete response, 28% partial response), with median overall survival of 17 months and 40% of patients surviving ≥1 year 2. A more recent single-center experience with 110 patients showed similar results: 19.1% complete response, 32.7% partial response, with median overall survival of 12.7 months 1.
For patients surviving ≥1 year after treatment, quality of life improvements were substantial: 50% gained weight, pain improved in 77%, performance status improved in 47%, and only 29% remained feeding-tube dependent 2.
Toxicity Profile
The regimen carries acceptable acute toxicity but requires monitoring:
- Acute toxicity: Grade ≥3 skin toxicity in 45% and mucosal toxicity in 65% of patients 2
- Severe late toxicity: Only 4.5% of patients 2
- Grade IV toxicity: Dermatitis in 2.7% and mucositis in 1.8%, occasionally requiring hospitalization 1
Clinical Context and Comparison
This differs fundamentally from curative-intent regimens recommended in guidelines. Standard definitive radiotherapy for head and neck cancer typically delivers 66-70 Gy in 2 Gy fractions over 6.5-7 weeks 3, or altered fractionation schemes reaching 70-81.6 Gy 4, 5. The Christie regimen's shorter duration (3.2 weeks vs. 6-7 weeks) and lower total dose make it appropriate specifically for palliative intent in patients with:
- Advanced unresectable disease not suitable for curative treatment
- Poor performance status precluding standard chemoradiation
- Resource-limited settings where prolonged treatment is impractical
Important Caveats
Do not confuse this with curative-intent treatment. The Christie scheme is explicitly a palliative regimen. For patients potentially curable, standard guidelines recommend 66-70 Gy with conventional fractionation or altered fractionation schemes 3. The biological equivalent dose of the Christie regimen (50 Gy in 3.125 Gy fractions) is substantially lower than curative doses, making it inappropriate for patients who could tolerate definitive treatment.
The regimen provides excellent symptom control and acceptable survival for its intended palliative population, with the advantage of shorter treatment duration reducing patient burden and healthcare resource utilization 1, 2.